https://doi.org/10.4081/ejh.2021.3255
Downregulation of Williams syndrome transcription factor (WSTF) suppresses glioblastoma cell growth and invasion by inhibiting PI3K/AKT signal pathway
Submitted: 25 March 2021
Accepted: 23 October 2021
Published: 17 November 2021
Accepted: 23 October 2021
Abstract Views: 613
PDF: 412
HTML: 30
HTML: 30
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Williams syndrome transcription factor (WSTF) participates in diverse cellular processes, including tumor cell proliferation and migration. However, the function of WSTF in glioblastoma (GBM) remains unknown. Data from the Gene Expression Profiling Interactive Analysis (GEPIA) and The Cancer Genome Atlas (TCGA) datasets showed that WSTF was up-regulated in GBM tissues. Moreover, WSTF was also increased in the GBM cells. pcDNA-mediated over-expression of WSTF contributed to cell proliferation and invasion of GBM cells, while GBM cell proliferation and invasion were suppressed by shRNA-mediated silencing of WSTF. Additionally, GBM cell apoptosis was reduced by over-expression of WSTF accompanied by decrease in Bax and cleaved caspase-3, while promoted by silencing of WSTF with increase in Bax and cleaved caspase-3. Protein expression of AKT phosphorylation was enhanced by WSTF over-expression while reduced by WSTF silencing. Inhibitor of phosphatidylinositol 3 kinase attenuated WSTF over-expression-induced increase in GBM cell proliferation and invasion. In conclusion, WSTF contributed to GBM cell growth and invasion through activation of PI3K/AKT pathway.
Lah TT, Novak M, Breznik B. Brain malignancies: Glioblastoma and brain metastases. Semin Cancer Biol 2020;60:262-73.
DOI: https://doi.org/10.1016/j.semcancer.2019.10.010
Campos B, Olsen LR, Urup T, Poulsen HS. A comprehensive profile of recurrent glioblastoma. Oncogene 2016;35:5819-25.
DOI: https://doi.org/10.1038/onc.2016.85
Jiang P, Mukthavavam R, Chao Y, Bharati IS, Fogal V, Pastorino S, et al. Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs. J Transl Med 2014;12:13.
DOI: https://doi.org/10.1186/1479-5876-12-13
Cho KS, Elizondo LI, Boerkoel CF. Advances in chromatin remodeling and human disease. Curr Opin Genet Dev 2004;14:308-15.
DOI: https://doi.org/10.1016/j.gde.2004.04.015
Xiao A, Li H, Shechter D, Ahn SH, Fabrizio LA, Erdjument-Bromage H, et al. WSTF regulates the H2A.X DNA damage response via a novel tyrosine kinase activity. Nature 2009;457:57-62.
DOI: https://doi.org/10.1038/nature07668
Culver-Cochran AE, Chadwick BP. Loss of WSTF results in spontaneous fluctuations of heterochromatin formation and resolution, combined with substantial changes to gene expression. BMC Genomics 2013;14:740.
DOI: https://doi.org/10.1186/1471-2164-14-740
Aydin ÖZ, Marteijn JA, Ribeiro-Silva C, Rodríguez López A, Wijgers N, Smeenk G, et al. Human ISWI complexes are targeted by SMARCA5 ATPase and SLIDE domains to help resolve lesion-stalled transcription. Nucleic Acids Res 2014;42:8473-85.
DOI: https://doi.org/10.1093/nar/gku565
Lundqvist J, Kirkegaard T, Laenkholm A-V, Duun-Henriksen AK, Bak M, Feldman D, et al. Williams syndrome transcription factor (WSTF) acts as an activator of estrogen receptor signaling in breast cancer cells and the effect can be abrogated by 1α,25-dihydroxyvitamin D3. J Steroid Biochem Mol Biol 2018;177:171-8.
DOI: https://doi.org/10.1016/j.jsbmb.2017.06.003
Liu Y, Wang S-Q, Long Y-H, Chen S, Li Y-F, Zhang J-H. KRASG12 mutant induces the release of the WSTF/NRG3 complex, and contributes to an oncogenic paracrine signaling pathway. Oncotarget 2016;7:53153-64.
DOI: https://doi.org/10.18632/oncotarget.10625
Dong C, Sun J, Ma S, Zhang G. K-ras-ERK1/2 down-regulates H2A.X(Y142ph) through WSTF to promote the progress of gastric cancer. BMC Cancer 2019;19:530.
DOI: https://doi.org/10.1186/s12885-019-5750-x
Alifieris C, Trafalis DT. Glioblastoma multiforme: Pathogenesis and treatment. Pharmacol Ther 2015;152:63-82.
DOI: https://doi.org/10.1016/j.pharmthera.2015.05.005
Annovazzi L, Caldera V, Mellai M, Riganti C, Battaglia L, Chirio D, et al. The DNA damage/repair cascade in glioblastoma cell lines after chemotherapeutic agent treatment. Int J Oncol 2015;46:2299-308.
DOI: https://doi.org/10.3892/ijo.2015.2963
Yang S, Quaresma AJC, Nickerson JA, Green KM, Shaffer SA, Imbalzano AN, et al. Subnuclear domain proteins in cancer cells support the functions of RUNX2 in the DNA damage response. J Cell Sci 2015;128:728-40.
DOI: https://doi.org/10.1242/jcs.160051
Chen W-L, Turlova E, Sun CLF, Kim J-S, Huang S, Zhong X, et al. Xyloketal B suppresses glioblastoma cell proliferation and migration in vitro through inhibiting TRPM7-regulated PI3K/Akt and MEK/ERK signaling pathways. Mar Drugs 2015;13:2505-25.
DOI: https://doi.org/10.3390/md13042505
Balça-Silva J, Matias D, Carmo Ad, Sarmento-Ribeiro AB, Lopes MC, Moura-Neto V. Cellular and molecular mechanisms of glioblastoma malignancy: Implications in resistance and therapeutic strategies. Semin Cancer Biol. 2019;58:130-41.
DOI: https://doi.org/10.1016/j.semcancer.2018.09.007
16. Shahcheraghi S, Tchokonte-Nana V, Lotfi M, Lotfi M, Ghorbani A, Sadeghnia H. Wnt/beta-catenin and PI3K/Akt/mTOR Signaling Pathways in Glioblastoma: Two Main Targets for Drug Design: A Review. Curr Pharm Design. 2020;26.
DOI: https://doi.org/10.2174/1381612826666200131100630
17. Crespo Pomar S, Arcaro A. The role of the PI3K/AKT/mTOR pathway in brain tumor metastasis. J Cancer Metastasis Treat 2016;2:80-9.
DOI: https://doi.org/10.20517/2394-4722.2015.72
Westhoff M-A, Karpel-Massler G, Brühl O, Enzenmüller S, La Ferla-Brühl K, Siegelin MD, et al. A critical evaluation of PI3K inhibition in glioblastoma and neuroblastoma therapy. Mol Cell Ther 2014;2:32.
DOI: https://doi.org/10.1186/2052-8426-2-32
Krassnig S, Wohlrab C, Golob-Schwarzl N, Raicht A, Haybaeck J. A profound basic characterization of eIFs in gliomas: Identifying eIF3I and 4H as Potential novel target candidates in glioma therapy. Cancers 2021;13:1482.
DOI: https://doi.org/10.3390/cancers13061482
Meng J, Zhang X-T, Liu X-L, Fan L, Li C, Sun Y, et al. WSTF promotes proliferation and invasion of lung cancer cells by inducing EMT via PI3K/Akt and IL-6/STAT3 signaling pathways. Cell Signal 2016;28:1673-82.
DOI: https://doi.org/10.1016/j.cellsig.2016.07.008
Oya H, Yokoyama A, Yamaoka I, Fujiki R, Yonezawa M, Youn M-Y, et al. Phosphorylation of Williams syndrome transcription factor by MAPK induces a switching between two distinct chromatin remodeling complexes. J Biol Chem 2009;284:32472-82.
DOI: https://doi.org/10.1074/jbc.M109.009738
Liu Y, Zhang Y-Y, Wang S-Q, Li M, Long Y-H, Li Y-F, et al. WSTF acetylation by MOF promotes WSTF activities and oncogenic functions. Oncogene 2020;39:5056-67.
DOI: https://doi.org/10.1038/s41388-020-1350-0
How to Cite
Yang, L., Du, C. ., Chen, H. ., & Diao, Z. . (2021). Downregulation of Williams syndrome transcription factor (WSTF) suppresses glioblastoma cell growth and invasion by inhibiting PI3K/AKT signal pathway. European Journal of Histochemistry, 65(4). https://doi.org/10.4081/ejh.2021.3255
Copyright (c) 2021 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- V. Pibiri, A. Ravarino, C. Gerosa, M.C. Pintus, V. Fanos, G. Faa, Stem/progenitor cells in the developing human cerebellum: an immunohistochemical study , European Journal of Histochemistry: Vol. 60 No. 3 (2016)
- Kazuhiko Hashimoto, Yutaka Oda, Fumihisa Nakamura, Ryosuke Kakinoki, Masao Akagi, Lectin-like, oxidized low-density lipoprotein receptor-1-deficient mice show resistance to age-related knee osteoarthritis , European Journal of Histochemistry: Vol. 61 No. 1 (2017)
- Yan Yan Li, Ya Ping Feng, Li Liu, Jin Ke, Xing Long, Inhibition of HMGB1 suppresses inflammation and catabolism in temporomandibular joint osteoarthritis via NF-κB signaling pathway , European Journal of Histochemistry: Vol. 66 No. 3 (2022)
- Paolo Flace, Diana Galletta, Antonella Bizzoca, Gianfranco Gennarini, Paolo Livrea, A candidate projective neuron type of the cerebellar cortex: the synarmotic neuron , European Journal of Histochemistry: Vol. 68 No. 2 (2024)
- G Natale, G Lazzeri, C Blandizzi, M Ferrucci, M Del Tacca, Differential distribution of transforming growth factor-a immunohistochemistry within whole gastric mucosa in rats , European Journal of Histochemistry: Vol. 47 No. 4 (2003)
- RM Ruggeri, S Sciacchitano, F Trimarchi, G Barresi, M Trovato, Expression of hepatocyte growth factor in Hashimoto’s thyroiditis with nodular lesions , European Journal of Histochemistry: Vol. 51 No. 3 (2007)
- K. Okamoto, N. Kiga, Y. Shinohara, I. Tojyo, S. Fujita, Effect of interleukin-1beta and dehydroepiandrosterone on the expression of lumican and fibromodulin in fibroblast-like synovial cells of the human temporomandibular joint , European Journal of Histochemistry: Vol. 59 No. 1 (2015)
- Antonella Vetuschi, Alfredo Cappariello, Paolo Onori, Eugenio Gaudio, Giovanni Latella, Simona Pompili, Roberta Sferra, Ferroptosis resistance cooperates with cellular senescence in the overt stage of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis , European Journal of Histochemistry: Vol. 66 No. 3 (2022)
- ML Rossi, N Marziliano, PA Merlini, E Bramucci, U Canosi, P Presbitero, E Arbustinie, PM Mannucci, D Ardissino, Phenotype commitment in vascular smooth muscle cells derived from coronary atherosclerotic plaques: differential gene expression of endothelial Nitric Oxide Synthase , European Journal of Histochemistry: Vol. 49 No. 1 (2005)
- F Corallini, A Gonelli, F D’Aurizio, MG di Iasio, M Vaccarezza, Mesenchymal stem cells-derived vascular smooth muscle cells release abundant levels of osteoprotegerin , European Journal of Histochemistry: Vol. 53 No. 1 (2009)
<< < 29 30 31 32 33 34 35 36 37 38 > >>
You may also start an advanced similarity search for this article.
